Related Experiment Video
Updated: Dec 30, 2025

09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
34.5K
POLR3A variants with striatal involvement and extrapyramidal movement disorder
Inga Harting1, Murtadha Al-Saady2, Ingeborg Krägeloh-Mann3
1Department of Neuroradiology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Neurogenetics
|January 16, 2020
Summary
This study identifies a distinct striatal variant of POLR3A-related disease, characterized by extrapyramidal symptoms and specific MRI findings, differing from 4H leukodystrophy.
Area of Science:
- Genetics
- Neurology
- Radiology
Background:
- Biallelic POLR3A variants typically cause 4H leukodystrophy, marked by hypomyelination and specific neurological signs, with basal ganglia spared.
- Atypical presentations of POLR3A variants involving the striatum and red nucleus have been rarely reported.
Purpose of the Study:
- To characterize a striatal variant of POLR3A-related disease.
- To differentiate this variant from classic 4H leukodystrophy based on clinical and MRI findings.
Main Methods:
- Retrospective review of clinical and genetic data from nine patients with POLR3A variants and striatal changes.
- Analysis of 18 MRI scans to identify characteristic radiological features.
Main Results:
- All patients presented with prominent extrapyramidal involvement, including hypotonia and choreic movements in younger children.
- Characteristic MRI findings included striatal T2-hyperintensity and atrophy, with superior cerebellar peduncle involvement.
- Distinct from 4H leukodystrophy, this variant showed no frank hypomyelination but abnormal myelination of specific tracts.
Conclusions:
- The striatal variant of POLR3A-related disease is clinically and radiologically distinct from 4H leukodystrophy.
- This variant is associated with specific intronic POLR3A variants (c.1771-6C>G or c.1771-7C>G) in combination with another POLR3A variant.
Related Concept Videos
Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Parkinson's Disease: Treatment
886
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
886
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K

